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The last decade has seen much progress in adjunctive cell therapy for immune disorders.
Both corporate and institutional Phase III studies have been run using mesenchymal stromal
cells (MSC) for treatment of Graft versus Host Disease (GvHD), and product approval has
been achieved for treatment of pediatric GvHD in Canada and New Zealand (Prochymal®;
Osiris Therapeutics). This effectiveness has prompted the prophylactic use of adherent
stem cells at the time of allogeneic hematopoietic stem cell transplantation (HSCT) to pre-
vent occurrence of GvHD and possibly provide stromal support for hematopoietic recovery.
The MultiStem® product is an adult adherent stem cell product derived from bone marrow
which has significant clinical exposure. MultiStem cells are currently in phase II clinical stud-
ies for treatment of ischemic stroke and ulcerative colitis, with Phase I studies completed
in acute myocardial infarction and for GvHD prophylaxis in allogeneic HSCT, demonstrating
that MultiStem administration was well tolerated while the incidence and severity of GvHD
was reduced. In advancing this clinical approach, it is important to recognize that alternate
models exist based on clinical manufacturing strategies. Corporate sponsors exploit the
universal donor properties of adherent stem cells and manufacture at large scale, with many
products obtained from one or limited donors and used across many patients. In Europe,
institutional sponsors often produce allogeneic product in a patient designated context.
For this approach, disposable bioreactors producing <10 products/donor in a closed sys-
tem manner are very well suited. In this review, the use of adherent stem cells for GvHD
prophylaxis is summarized and the suitability of disposable bioreactors for MultiStem pro-
duction is presented, with an emphasis on quality control parameters, which are critical
with a multiple donor approach for manufacturing.
Keywords: MultiStem cells, GvHD prophylaxis, regenerative medicine, adherent stem cells, bioreactor
RATIONALE FOR ADHERENT STEM CELLS IN PROPHYLAXIS
Graft versus Host Disease (GVHD) is a potential life-threatening
complication and one of the major limitations of allogeneic
hematopoietic stem cell transplantation (HSCT). The compli-
cation is thought to be initiated by activation of mature donor
T-cells, which are co-infused with the hematopoietic stem cell
(HSC) transplant, through recognition of target antigens pre-
sented on MHC molecules expressed on antigen presenting cells
that reside within host tissue. Upon alloantigen recognition, the
co-infused donor T-cells become activated, expand, and induce
cytolytic effects that target several organs including skin, gut, and
liver.
Current therapies to prevent acute GvHD (aGvHD) make
use of pharmacological suppression of T-cell activation, however,
such immunomodulatory therapy appears not sufficient to treat
a GvHD and it may increase the risk of opportunistic infections
(Perales et al., 2007) and disease relapse (Lee et al., 2004). Addi-
tional strategies are thus required to improve the response rate to
immunosuppression.
The last decades have seen major improvements in stem cell
research and the translational application of adult stem cells (Arm-
strong et al., 2012). This has led to numerous clinical trials to
investigate the efficacy of various types of stem cells to treat
immune disorders, neurodegenerative and cardiovascular disease,
bone and cartilage repair, and type I diabetes (Busch et al., 2011b;
Trounson et al., 2011; Penn et al., 2012).
Adherent non-hematopoietic bone marrow-derived stem cells
have been demonstrated to reduce proliferation of GvHD patient-
derived T-cells (Le Blanc et al., 2004), inhibit alloreactive T-cell
responses and support HSC engraftment (Auletta et al., 2010).
Their use has therefore gained particular interest to treat and pre-
vent GvHD in patients with hematopoietic malignancies such as
acute myeloid or lymphoid leukemia (AML,ALL),chronic myeloid
leukemia (CML), or myelodysplasia (MDS).
MULTISTEM CELLS
Multipotent adult progenitor cells (MAPC) are bone-marrow-
derived non-hematopoietic adherent cells that were first described
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by Jiang et al. (2002). The MultiStem clinical product is based on
MAPC isolation and expansion protocols (Boozer et al., 2009).
Pre-clinical animal studies have clearly shown therapeutic benefits
of MAPC/MultiStem cells by preventing GvHD (Kovacsovics-
Bankowski et al., 2009), and improving tissue regeneration and
function in cardiovascular and neurological disorders, including
acute myocardial infarct, traumatic brain injury, spinal cord injury,
and ischemic limb injury (van’t Hof et al., 2007; Aranguren et al.,
2008, 2011; Mays et al., 2010; Walker et al., 2010, 2012; Busch et al.,
2011a).
MultiStem cells are in Phase II clinical testing for use in treat-
ment of inflammatory bowel diseases (ulcerative colitis), acute
myocardial infarct, and ischemic stroke. Safety studies (Phase I
clinical trials) using MultiStem as an adjunct in allogeneic bone
marrow transplantation for prevention of GvHD (Maziarz et al.,
2012) and acute myocardial infarction (AMI) have been completed
(Penn et al., 2012). Table 1 summarizes the current status of the
MultiStem (pre)clinical trials.
The therapeutic benefits of MAPC are multimodulatory and
have been shown to be caused, at least in part, by their pro-
angiogenic effect through trophic support (Aranguren et al.,
2007, 2011; Lehman et al., 2012) and their ability to modu-
late the immune system (Kovacsovics-Bankowski et al., 2009;
Walker et al., 2010). In particular the immune-regulatory prop-
erties are of paramount importance for GvHD treatment. Human
and rodent MAPC are non-immunogenic. The cells lack MHC II
expression, and therefore do not induce a proliferative response
when co-cultured with allogeneic T-cells (Kovacsovics-Bankowski
et al., 2009; Jacobs et al., 2012). These studies showed that
MAPC significantly reduce T-cell proliferation when respon-
der T-cells are stimulated with allogeneic irradiated stimula-
tor cells. The study by Kovacsovics–Bankowski furthermore
demonstrated the absence of MAPC in vivo immunogenicity,
since injection of allogeneic Lewis rat MAPC into Buffalo rats
failed to prime an anti-Lewis T-cell response as was observed
with allogeneic splenocytes. This immuno-privileged nature and
capacity of human and rodent MAPC to inhibit T-cell prolif-
eration is of importance for their use in GvHD prophylaxis.
A study by Highfill et al. (2009) demonstrated that MAPC
had a prophylactic effect on GvHD after intrasplenic injec-
tion. Improved animal survival was seen in MAPC treated mice,
while reduced CD4+ and CD8+ T-cells in the spleen were
observed.
The effect of MAPC on the inhibition of T-cell prolifera-
tion in the study by Highfill and coworkers was shown to be
dependent on the ability of MAPC to express PGE synthase and
the production of prostaglandin E2 (PGE2). Other studies have
also shown that MAPC immunosuppression is partially medi-
ated by soluble factors. A role for indoleamine 2,3-dioxygenase
has been demonstrated for human and rat MAPC (Kovacsovics-
Bankowski et al., 2009; Jacobs et al., 2012), but this was not
found in murine MAPC (Highfill et al., 2009). On the contrary,
blocking PGE2 activity had no effect on the suppressive effect of
human MAPC (Jacobs et al., 2012) indicating that the molecu-
lar mechanisms of immunosuppression occur in a species specific
manner.
MULTISTEM CELLS VERSUS MSC
Mesenchymal stromal cells (MSC) may use similar immunosup-
pression mechanisms (Gebler et al., 2012) and although MAPC
and MSC exert comparable activity in an in vitro T-cell suppres-
sion assay (Jacobs et al., 2012), it is evident that they are distinct
cell types. Both cells are adherent bone marrow-derived stem cells,
but due to different culture conditions they adopt different pheno-
types (Roobrouck et al., 2011b). The cells express distinct cytokine
profiles which may explain the observations that MAPC can induce
tube formation by HUVEC cells in in vitro assays while MSC lack
this pro-angiogenic effect (Lehman et al., 2012). Moreover, MAPC
are able to induce functional blood vessels in vivo when the cells
are implanted in a Matrigel plug with VEGF and bFGF under the
skin of nude mice, where vessels induced by MSC appeared leaky
(Roobrouck et al., 2011a). This latter study showed by means of
transcriptome analysis that MAPC and MSC are clearly distin-
guishable cells types. In a recent study, intracranial injection of
human MAPC and human MSC 2 days after induction of stroke
revealed that MAPC had a stronger effect on the attenuation of the
inflammatory response and had more potency to promote endoge-
nous tissue regeneration than MSC (Mora-Lee et al., 2012). Thus
differences in in vivo activity between MAPC and MSC have been
described, but it is not clear yet how this relates for instance to the
therapeutic activity of these cells in GvHD prophylaxis.
MAPC and MultiStem cells are thus immune-privileged in the
currently tested settings, and for MSC low-immunogenicity and
an anatomical site-specific immuno-privileged nature have been
demonstrated (reviewed by Griffin et al., 2010). Before safe appli-
cation as an allogeneic cell product to patients, cells need to be
isolated, expanded, and quality tested in order to reach sufficient
cells with therapeutic activity. This hampers the use of autologous
cells for applications where cells are needed immediately, as is the
case for stroke for instance. Particularly MAPC and MultiStem
cells have the capacity to undergo extensive expansion doublings
in vitro, which, combined with the immuno-privileged properties,
enable an off-the-shelf use for MultiStem cells, with therapeutic
product available at the time of need and usable without patient
matching.
Pre-clinical animal studies using multipotent MSC in HSCT
have shown positive effects on survival benefit and the prevention
of GvHD, although contradictory effects are observed depending
on the origin of adherent stem cells, timing, and dose of infu-
sion (see reviews by Auletta et al., 2010; Baron and Storb, 2012).
Pre-clinical studies have shown safety for intravenous infusion of
MultiStem cells and demonstrated that the survival rate in a hap-
loidentical aGvHD rat model increased from less than 20 to 50%
in rats that received two MultiStem doses in a prophylactic manner
(Kovacsovics-Bankowski et al., 2008, 2009).
Human clinical studies have been conducted to evaluate the
safety and efficacy of MSC to treat GvHD. Review of current data
show that the application of MSC is safe, but that inconsistent
benefit is seen in the treatment of acute and steroid-refractory
GvHD (Ball et al., 2008; Auletta et al., 2010; Kebriaei and Robin-
son, 2011a,b; Baron and Storb, 2012). While these first studies are
encouraging and prompt evaluation of optimal dosing strategies
for MSC treatment of active clinical GvHD, an equally important
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strategy is the use of adherent stem cells as adjunct to HSC for
prophylaxis of GvHD. To date a limited number of clinical stud-
ies have been conducted to investigate co-transplantation of MSC
with HSC and the prevention of GvHD. Recently a phase I clinical
dose escalation study was finished in which MultiStem cells were
administered to adult patients undergoing allogeneic HSCT for
the treatment of leukemia and related conditions (Maziarz et al.,
2012).
CLINICAL EXPERIENCE USING ADHERENT STEM CELLS AS
HSCT CO-TRANSPLANT
Several studies have evaluated the effect of MSC co-
transplantation with HSC on engraftment, safety, and GvHD in
pediatric (Ball et al., 2007; Macmillan et al., 2009; Bernardo et al.,
2011) and adult patients (Lazarus et al., 2005; Ning et al., 2008;
Baron et al., 2010; Table 2). Ball et al. (2007) reported a Phase
I/II trial in which 14 children received 1–5 million donor MSC/kg
body weight 4 h before peripheral blood stem cell (PBSC) trans-
plantation of HLA-disparate relative donors. No infusion-related
toxicity was observed. Graft rejection did not occur in the 14
patients receiving MSC, while seven graft failures were observed
in a historic control group of 47 children.
A decreased incidence of aGvHD was observed in a group of
13 pediatric hematological disorder patients who received paternal
HLA-disparate MSC co-transplantation with umbilical cord blood
cells (Bernardo et al., 2011). Single dose injections of 1–3.9 million
MSC/kg body weight were safe and revealed no significant differ-
ence of cumulative graft rejection when compared with a group
of 39 historical controls. Grade II–IV aGvHD showed no signifi-
cant difference between MSC-receiving patients and controls (31
versus 41%, p=NS). However, patients in the MSC group did
not develop grade III or IV aGvHD, while the incidence of these
severe forms in the control groups was 26% (p= 0.05). None of
the patients developed cGvHD, while 11% were observed in the
control (p=NS).
Macmillan et al. (2009) reported another Phase I/II clinical
trial in pediatric patients receiving MSC co-transplanted with
umbilical cord blood transplantation. Eight patients received
a dose of 0.9–5 million MSC/kg body weight MCS of hap-
loidentical parental donors, 4 h prior to transplantation of unre-
lated donor blood cell and three of them were given a sec-
ond dose at day 21. Three patients developed grade II GvHD,
and no patient developed cGvHD. No statistical difference with
a historical cohort was observed, but the authors mention a
Table 2 | Summary of clinical studies using adherent stem cells for GvHD prophylaxis.
Study HSCT specifics Stromal cell therapy Stromal cell dosing Observations
Maziarz
et al. (2012)
URD, MRD, BM/PB,
Adults CSA+MTX,
Tac+MTX
Third party, universal
donor, GHVD
prophylaxis
1, 5, or 10 million/kg, single
dose day 2 after HSCT, or 1 or
5 million/kg repeat dose on
day 2, 9, and 16, or days 2, 9,
16, 23, and 30 after HSCT
Grade II–IV and III–IV GVHD at Day 100 was 37 and
14%, resp. (n=36). 11% II–IV GVHD and no grade
III–IV GVHD and in 10 million/kg group single dose
(n=9). Anticipated rates in this population; 47%
II–IV and 15% III–IV
Kuzmina
et al. (2012)
RD, HSCT, adults CSA,
MTX, prednisolone
HSC donor-derived
MSC, GVHD treatment
0.9–1.3 million/kg, 19–54 days
after HSCT
Grade II–IV aGVHD in 33.3% of control patients
and 5.3% in MSC prophylaxis group
Bernardo
et al. (2011)
URD, RD, UCB, pediatric
CSA+ steroids,
CSA+MTX
Paternal derived MSC,
GVHD prophylaxis
1–3.9 million/kg, single dose
at day of HSCT
Reduced grade III–IV GVHD (0%, compared to
historic controls 18/8%)
Baron et al.
(2010)
URD, PB, adults
MMF+Tac
Unrelated MSC, safety
of MSC
co-transplantation
1–2 million/kg at day of HSCT Day 100 incidence of grade II–IV was 35%.
Cumulative incidence of grade II–IV GVHD was
45%, compared with 56% in historic group
Macmillan
et al. (2009)
URD, UCB, pediatric
CSA+ steroids
Parental MSC, promote
engraftment
0.9–5 million/kg at day of
HSCT; three patients second
dose at day 21
At day 100, cumulative incidence of grade II–IV
similar between MSC and historic control (38
versus 22%, p=0.44)
Ning et al.
(2008)
RD, BM/PB, adult
CSA+MTX
Sibling derived MSC,
MSC prophylaxis
0.03–1.53 million/kg at day of
HSCT
Grade II–IV was 11.1% in MSC group and 53.3% in
non-MSC group. Overall aGVHD incidence was
44.4% in MSC and 73.3% in non-MSC group
Ball et al.
(2007)
MRD, PB, pediatric HSC donor-derived
MSC, graft failure
1–5 million/kg single dose at
day of HSCT
No graft rejection in patients receiving MSC, 14.8%
failure in control group (p=0.14)
Lazarus
et al. (2005)
RD, PB/BM, adults
CSA+MTX
HSC donor-derived
MSC, GVHD
prophylaxis
1, 2.5, or 5 million/kg single
dose at day of HSCT
Overall, 50% of patients developed aGVHD, at
least grade II in 28% of patients. 11 and 4%
developed grade III and IV respectively
URD, unrelated donor; MRD, mismatched related donor; RD, related donor; BM, bone marrow; PB, peripheral blood; UCB, umbilical cord blood; CSA, cyclosporine;
MTX, methotrexate; Tac, tacrolimus.
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non-significant trend toward improved 3-year survival in the MSC
group.
A study by Lazarus et al. (2005) was done on 46 adult
patients receiving bone marrow (n= 19) or PBSCs (n= 27) co-
transplanted 1–5×million/kg MSC from HLA-identical sibling
donors. A total of 28% of the patients developed at least grade
II aGvHD, while grade III and IV were observed by 11 and 4%
respectively. The authors indicate a literature-based percentage of
44–64% for grade III and 12–26% for grade IV, suggesting a benefit
of MSC infusion.
Ning et al. (2008) compared patients receiving HLA-identical
sibling HSCs from blood or bone marrow without (n= 15) or
with (n= 10) co-transplantation of MSC (0.3–15.3× 105/kg body
weight). Grade II–IV GvHD was developed in 11% of the MSC
group and 53% of the non-MSC group. None of the patients in
both groups showed grade III–IV aGvHD.
Baron et al. (2010) performed a safety study in which patients
were transplanted with PBSCs from HLA-mismatched donors in
combination with MSC from third party unrelated donors. Twenty
patients were co-infused with PBSC and 1–2 million MSC/kg body
weight and compared with historical group of 16 patients treated
with unrelated donor PBSC without MSC. In the MSC group, 45%
experienced grade II–IV aGvHD and 56% in the control group.
Grade IV aGvHD developed in 10% of the MSC group and 19%
in the historic group.
The studies by Bernardo, Ning and Baron show that develop-
ment of aGvHD after HSC transplantation may be reduced after
co-injection of MSC. Efficacy of MSC as a therapy for aGvHD has
recently also been reported by Kuzmina et al. (2012). In this study
the MSC were administered after HSCT at the time of graft activa-
tion and GvHD manifestation and the authors showed a significant
reduction of the incidence of grade II–IV aGvHD in the group of
patients having received MSC. The combined results provide a
promising base for adherent stem cells as an adjunct therapy for
graft support and GvHD prophylaxis. Still, the number of studies
and evaluated patients remain limited, and additional evaluations
are essential to determine optimal cell dose, timing, and frequency
of administration in achieving maximum clinical benefit.
MULTISTEM THERAPY FOR PROPHYLAXIS OF ACUTE GvHD
The primary objective of the clinical Phase I study was to evaluate
the safety of MultiStem administration in single dose or as repeat
doses to patients receiving allogeneic HSCT (Maziarz et al., 2012).
A total of 36 patients was treated with MultiStem, 18 each in the
single dose arm (1, 5, and 10 million cells/kg on day 2 after trans-
plant) or the repeated dose arm (1 or 5 million/kg on days 2, 9,
and 16 (3 weekly doses), or 5 million/kg on days 2, 9, 16, 23, and
30 (5 weekly doses).
The study demonstrated that MultiStem therapy was well toler-
ated in both the single infusion and repeat infusion arms and also
suggested that the therapy may provide benefit to recipients of allo-
geneic HSCT, such as reducing the incidence and severity of GvHD,
as compared to historical clinical experience (Ratanatharathorn
et al., 1998; Nash et al., 2000; Anasetti et al., 2011). The majority
of patients participating in the study received transplants from
unrelated donors (19 of 36), and nearly all of the patients received
PBSC transplants (34 of 36), both of which are associated with a
higher risk of GvHD. Importantly, all patients experienced success-
ful neutrophil engraftment (median time of engraftment 15 days),
and 86% of patients experienced successful platelet engraftment
(median time of engraftment 16 days) which compares favorably
to historical clinical experience for this patient population sup-
porting a positive impact on blood and immune system recovery.
Relative to the published experience for this specific patient pop-
ulation (Ratanatharathorn et al., 1998; Nash et al., 2000; Anasetti
et al., 2011), there was a substantial reduction in aGvHD incidence
after administration of the highest single dose of 10 million Mul-
tiStem cells/kg, i.e., 11% grade II–IV GvHD, and 0% grade III–IV
GvHD, versus 45–70 and 15–20%, respectively. There appeared to
be a trend in dose response relationship, with patients receiving the
highest single dose of MultiStem cells having a 33% lower absolute
incidence of aGvHD relative to patients who received a single low
or medium dose, and patients receiving once weekly dosing of
the medium dose through the first 30 days having reduced GvHD
incidence relative to single or weekly dosing over the first 2 weeks
post-transplant. Finally, relapse-free survival rate at 100 days and
infection-related complications over the first 100 days were favor-
able relative to historical clinical experience, consistent with the
positive effect on engraftment rates.
CHALLENGES IN STEM CELL THERAPEUTIC PRODUCT
DEVELOPMENT
Review of the stromal cell co-transplant and GvHD prophylaxis
studies summarized above reveal an important limitation to the
complete and optimal use of MSC as an effective therapy. Three of
the studies could not be performed as planned because of insuf-
ficient availability of MSC at the time of transplantation (Lazarus
et al., 2005; Ning et al., 2008; Macmillan et al., 2009). As a result,
patients were not injected, not given a repeat dose, or given lower
doses of MSC. This illustrates that the use of donor-related MSC
is hampered by the limited proliferative capacity of these cells
and/or sub-optimal cell expansion protocols or procedures. For
efficient therapeutic application in the clinic, most of these limita-
tions would be overcome by use of an allogeneic of-the-shelf stem
cells product that is expanded to large scale with consistency in
yields and quality.
To illustrate how the cell dose requirements for clinical studies
impact the associated expansion and quality control needs we will
detail the MultiStem study as a paradigm. For the completion of
the entire MultiStem GvHD study, a total of 35 billion cells were
injected, all of which were derived from expansions of seed-stock
obtained from a single donor. Current MultiStem production units
contain a surplus of cells, and consequently, over 50 billion cells
were required for this trial. Of course, a multiplicity of cells will
be needed for future trials and new manufacture procedures are
required to produce the cells in a safe and cost-effective manner.
Current process development efforts focus on the optimization of
stem cell manufacturing in order to achieve a consistent and safe
product for off-the-shelf use.
MULTISTEMMANUFACTURING
One of the most advantageous features of MultiStem cells is
the proliferative capacity, and cells can undergo more than 60
population doublings (PD) before senescence. The extensive
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proliferation capacity allows creation of a master and working
cell bank as production intermediates. The current manufactur-
ing strategy is based on clinical doses generated at about PD28
(master cell bank campaign) or PD38 (working cell bank cam-
paign) that allows for the production of >100,000 clinical doses
from a single donor.
MultiStem clinical production is currently performed by a con-
tract manufacturing organization (Lonza) for creation of master
cell banks and for production campaigns starting from those
banks. A production run typically generates 40–50 clinical doses.
The clinical dose varies according to indication, but current pro-
duction units contain 180 million cells. The cells are cryopreserved
and stored in a mixture of PlasmaLyte, i.e., an isotonic solution
that mimics human plasma electrolytes, pH and osmolality (Bax-
ter), DMSO, and human serum albumin. Each production run is
tested for adventitious agents such as sterility, mycoplasma, and
endotoxin. The product is also tested to show a normal karyotype.
Only after completion and validation of all tests, the product is
released from the contract manufacturer and stored for sites that
take part in MultiStem clinical trials. Currently, the product has a
validated shelf-life of 5 years.
MULTISTEM CELL EXPANSION IN A HOLLOW-FIBER
BIOREACTOR
The Quantum Cell Expansion System (TerumoBCT) is being
explored as an alternate platform for larger scale cell culture. This
instrument was developed for ex vivo expansion of stem cells using
a hollow-fiber bioreactor (Antwiler et al., 2009). The functionally
closed automated culture system is comprised of a disposable syn-
thetic hollow-fiber bioreactor of 2.1 m2 surface area connected to
a sterile closed-loop, computer-controlled media perfusion plat-
form and gas exchangers. In addition, the system contains sterile
closed sample ports by which fluid samples can be taken dur-
ing expansion in order to monitor expansion and estimate the
appropriate moment of harvest.
The Quantum system has been tested to optimize the com-
plete workflow of MultiStem culture in a two-step procedure of
stem cell isolation from bone marrow and subsequent expansion
up to the scale of clinical dose. During the first step, whole bone
marrow is loaded onto a bioreactor and maintained for 10 days,
yielding 1× 107 MultiStem cells. These cells are loaded onto a new
bioreactor and expanded to 1× 109 cells within a period of 6 days.
Thus five doses of 180 million cells are obtained by using two
consecutive runs on this bioreactor. This encourages the further
exploration of this system to upscale MultiStem batches that are
sufficient for clinical studies.
A crucial aspect of the research is to confirm by means of in vitro
cell equivalency testing that the expanded cells are of consistent
high quality and that cellular features that relate to in vivo function
are maintained after manufacture adjustments (Figure 1).
MULTISTEM QUALITY CONTROL AND EQUIVALENCY
TESTING
In advancing toward a final optimized manufacturing process,
modifications of the MultiStem manufacturing process are exten-
sively controlled in order to keep a consistent quality of the
product. A panel of cell assays has been developed that allows
for MultiStem QC testing in a tiered testing strategy (Figure 1).
First, MultiStem identity is measured by marker gene and protein
expression analysis by means of QPCR, ELISA, and flow cytom-
etry. For MultiStem batches that pass these criteria, multilineage
differentiation assays that are typically associated with stem cells
from mesenchymal origin are performed. Osteogenic, adipogenic,
and chondrogenic differentiation are measured by means of in situ
cytochemistry and specific gene induction profiles associated with
the corresponding cell types. As indicated above, one of the Multi-
Stem product’s mode of action in vivo has been shown to be based
on pro-angiogenic activity, which is supported by an in vitro tube
formation assay correlated with in vivo angiogenic activity and
cytokine expression (Lehman et al., 2012).
FIGURE 1 |The MultiStem QC pipeline. A full characterization of the
MultiStem product is being conducted after each important adjustment of the
manufacturing procedure. First, a standard QC is performed to establish
MultiStem growth and typical stem cell properties (left panel). Subsequently,
high throughput screens are performed to investigate the molecular
phenotype of MultiStem (right panel). The Cellavista image-based platform
(Roche) is used to study various morphological aspects of different cell
cultures. Genome-wide molecular phenotype analyses are carried out on
different platforms including array technology, PCR-based screening, and
next-generation sequencing (NGS). Combining these “omics” data facilitates
on the one hand the identification of unique MultiStem features, while on the
other hand the retention of the molecular identity after applying alternative
culturing methodologies can be validated. For MultiStem equivalency testing,
the immunosuppressive capacity is evaluated by two assays: one is based on
inhibition of T-cell proliferation and the other is based on the corresponding
reduction of IFNγ secretion by T-cells.
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Given the indications that inhibition of T-cell proliferation
is a major contributor to immune suppression by stromal cells,
we consider in vitro immune suppression and potency assays
as highly important in our QC in order to guarantee a consis-
tently safe product for treatment of GvHD and other disorders.
With the purpose of application in GvHD and other disorders
in which immunosuppression by MultiStem cells is critical, our
QC emphasizes on in vitro assays that reflect such suppression
(Kovacsovics-Bankowski et al., 2009). An in vitro criterion that is
often used to assess the immunosuppressive capacity of stem cells
is their inhibitory effect on the proliferation of activated T-cells. In
our QC we use two different standardized assays to quantify Mul-
tiStem immunosuppression. One of the assays directly measures
the inhibition of T-cell proliferation in a co-culture model of Mul-
tiStem cells and responder T-cells that are activated by CD3/CD28
or PBMC (Jacobs et al., 2012) while the other assay quantifies
interferon gamma (IFNγ) which is secreted by activated T-cells.
In the context of biosafety, a normal karyotype is demonstrated
by means of copy number variation (CNV) analysis of MultiStem
cells and donor-derived non-expanded mononuclear cells on SNP
arrays and the data is analyzed for genomic insertions or deletions
at a resolution of 50 kb.
EPIGENETIC SCREENS FOR CELL EQUIVALENCY TESTING
Our current QC pipeline is sufficient to determine MultiStem
identity and lot release assays for early to mid-stage clinical stud-
ies. However, it is anticipated that for late stage clinical trials
(Phase III) and product release, more stringent quality controls
are required by the regulatory organizations FDA and EMA, par-
ticularly in terms of potency and comparability following process
improvements. The QC pipeline is being extended with various
genome-wide screening methods to comprehensively characterize
the molecular phenotype of our product. Transcriptome analysis
is already implemented as a powerful tool in cell comparability
testing, and we currently explore emerging epigenetic analysis
tools that on the one hand identify robust MultiStem markers and
on the other hand provide insight in the mechanisms underlying
MultiStem function.
One of the epigenetic tools to investigate MultiStem identity
and comparability is miRNA screening, since miRNA profiles
determine the identity of stem cells (Chen et al., 2007) and distin-
guish between embryonic or adult stem cells, as well as between the
adult stem cells MAPC and MSC (Aranda et al., 2009). Epigenetic
modifications such as DNA methylation or histone modification
can influence the function of the associated genes. As a con-
sequence, stem cell identity is related to the epigenetic profile
and differentiation capacity is determined by epigenetic com-
ponents, including DNA methylation and histone modification
(Bloushtain-Qimron et al., 2009; Weishaupt et al., 2010). Epige-
netic processes can become altered by cell culture processes, since
methylation of genes related to differentiation can change dur-
ing in vitro passaging (Bork et al., 2010), while the maintenance
of unmethylated regions appears serum-dependent (Dahl et al.,
2008). This underscores that monitoring of epigenetic processes
may lead to a breakthrough in therapeutic stem cell manufacturing
development. Recently, a next-generation sequencing methodol-
ogy was started to map cytosine methylated regions in MultiStem
cells and to explore the possibility of identifying DNA methylation
markers. An additional epigenetic assay that is under development
to distinguish MultiStem cells from other adherent stromal cells
such as MSC is based on telomere biology, an important predictor
for proliferative capacity, and it was recently shown that MultiStem
telomerase activity is much higher than that of MSC (Boozer et al.,
2009).
Altogether, these assays will serve as controls for epigenetic
stability, and the product uniqueness and consistency, in partic-
ular after modification of the MultiStem manufacture procedure.
Application of these QC assays confirmed that characteristics of
MultiStem cells harvested from the Quantum Cell Expansion
System were maintained compared to those under standard cell
culture conditions (data not shown). All QC assays performed
thus far indicate successful MultiStem expansion in this bioreactor
format, with significant advantages in air-handling requirements
and reductions in labor.
PERSPECTIVE
Currently for the stromal cell therapy field as a whole, and for
MultiStem in particular, the development is still mainly in the pre-
clinical and early and mid clinical stages, during which safety and
dose effects are being evaluated. The optimal dosing strategy for
stromal cells is considered to be the composite of optimal individ-
ual dose level/administration and minimal number of adminis-
trations required to fully cover therapeutic opportunity windows.
E.g., in the case of GvHD prophylaxis, the therapeutic window cov-
ers 30–45 days after allo HSCT. Ideally, clear efficacy is observed
after infusion of a single dose level of cell product, but this has not
consistently been the experience in pre-clinical or clinical evalua-
tions (Table 2). As a consequence, current manufacture strategies
are based on the anticipated need to repeat infuse medium to
high dose levels (5–10 million cells/kg of bodyweight) in order to
observe efficacy. This equates roughly to 400 million to 1 billion
cells/infusion, or >1 billion cells/patient for repeat administra-
tion, which levels are outside of the range for MSC production
from individual donors on a consistent scale. This is especially the
case in context of anticipated late stage Phase III clinical studies
with large numbers of subjects (>100). However, for the Multi-
Stem product these cell requirements can feasibly be covered with
material from individual donors by using a staged expansion and
banking approach based on the extensive expansion capacity of
the MultiStem platform.
In all, the early clinical observations indicate that the class
of stromal stem cells can be safely infused via single or repeat
dose regimens in humans without long-term complications. There
are no apparent disadvantages of MultiStem per se, compared
to MSC. Still, continued clinical evaluation and scrutiny will
be required to address the still fairly limited experience with
immune sensitization as a consequence of repeat dosing of
allogeneic product, or long-term risk of ectopic tissue forma-
tion, especially in immune-compromised subjects. One remain-
ing shared disadvantage in current use of MultiStem and MSC
is the use of FBS for product manufacture and this will be
a major area of need in the development of next-generation
cell therapy products. Immune responses have been detected
against serum components on the stromal cells, but no significant
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alloantibody production has been reported (Spees et al., 2004;
Sundin et al., 2007). Completion of a serum-free workflow will
be beneficial because of limited serum availability, batch-to-batch
differences, the possibility of adventitious pathogens and ethical
considerations. It is anticipated that Phase III studies using Multi-
Stem in several clinical indications will have integrated serum-
free media formulation and production in a closed bioreactor
format.
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